Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company focused on advancing cancer therapies based on novel deoxyribonucleic acid (DNA) damage response (DDR) technologies. The Company’s research programs include kt-2000, kt-3000 and kt-4000 The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating deoxyribonucleic acid (DNA) double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cell’s DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.
Metrics to compare | RKV | Peers Peers - average of corresponding metrics from companies closely matching RKV: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRKVPeersSector |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | 0.0x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 0.0x | |
Price / LTM Sales | 0.0x | 0.0x | 0.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 0.0% | |
Fair Value Upside | Unlock | 0.0% | 0.0% | Unlock |